News

Novo Nordisk and Septerna have announced a new partnership worth $2.2bn to develop oral small molecule drugs for type 2 ...
Novo Nordisk is partnering with the biotech Septerna to develop oral obesity drugs, as it aims for more convenient weight ...
Despite competitive pressures in the obesity market, long-term investors may stay invested in NVO stock due to strong demand ...
Novo Nordisk CEO steps down after pressure from shareholders. Former CEO to join board as observer. Company remains ...
Announced Global Collaboration with Novo Nordisk to Develop Oral Small Molecules for Metabolic Diseases with Over $2.2 Billion in Potential Milestone Payments On Track to Select a Next-Generation Oral ...